Published Date: 14 Nov 2025
Neuroblastoma remains one of the deadliest childhood malignancies, accounting for a disproportionate number of pediatric cancer deaths worldwide.
Read Full NewsPolverino stresses the need for prospective analysis to validate CC16 and mucus plugs as viable biomarkers for COPD status.
In a recently published study, integrating prehospital GFAP measurements with established stroke scales significantly improved the accuracy of large vessel occlusion detection in patients with acute stroke.
Here's some of what is coming soon to NeurologyLive® this week.
Inside MS: A Clinician's Compass, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Edith Graham, MD. [LISTEN TIME: 40 minutes]
Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.
In this end-of-year reel, HCPLive has showcased several key highlights from the Skin of Color Savvy podcast in 2025.
This episode of Skin of Color Savvy was filmed on-site at the Skin of Color Society's 'Meeting the Challenge Summit' in Washington, DC.
1.
Does pollution cause cancer?
2.
A promising medication could slow brain tumors in children.
3.
ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death
4.
Invest in generics as a lesson from the shortages of chemotherapy.
5.
According to JAMA, even four minutes a day of exercise can lower the risk of cancer.
1.
The Mysterious Pain of Scrotal Hematoma: A Guide to Diagnosis and Treatment
2.
Exploring New Treatment Strategies for Mantle Cell Lymphoma
3.
Hemoglobin C: Understanding its Role in Sickle Cell Disease
4.
Mechanisms, Efficacy, and Survival Outcomes in AML, Squamous Cell Carcinoma, & Non-Hodgkin Lymphoma
5.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
2.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
3.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation